Sarepta Therapeutics, Inc.

NasdaqGS:SRPT Stock Report

Market Cap: US$2.1b

Sarepta Therapeutics Past Earnings Performance

Past criteria checks 0/6

Sarepta Therapeutics has been growing earnings at an average annual rate of 27.2%, while the Biotechs industry saw earnings growing at 21.8% annually. Revenues have been growing at an average rate of 32.2% per year.

Key information

27.18%

Earnings growth rate

30.20%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate32.17%
Return on equity-20.57%
Net Margin-11.25%
Last Earnings Update30 Sep 2025

Recent past performance updates

Recent updates

Sarepta Therapeutics: Is Elevidys A Bust?

Jan 16

There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues Despite A 35% Share Price Rise

Dec 04
There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues Despite A 35% Share Price Rise

Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Shares Bounce 32% But Its Business Still Trails The Industry

Oct 18
Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Shares Bounce 32% But Its Business Still Trails The Industry

We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right

May 29
We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right

The Consensus EPS Estimates For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Just Fell A Lot

May 08
The Consensus EPS Estimates For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Just Fell A Lot

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Not Doing Enough For Some Investors As Its Shares Slump 27%

Apr 20
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Not Doing Enough For Some Investors As Its Shares Slump 27%

Sarepta: Disclosure Of An Elevidys Patient's Death Creates Market Uncertainty

Mar 18

Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Low P/S No Reason For Excitement

Mar 05
Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Low P/S No Reason For Excitement

Sarepta Therapeutics' Long-Term Potential Intact Despite Near-Term Stock Weakness

Mar 04

These 4 Measures Indicate That Sarepta Therapeutics (NASDAQ:SRPT) Is Using Debt Reasonably Well

Jan 22
These 4 Measures Indicate That Sarepta Therapeutics (NASDAQ:SRPT) Is Using Debt Reasonably Well

Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely

Jan 16

Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Healthy Earnings, But It Is Not All Good News

Nov 13
Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Healthy Earnings, But It Is Not All Good News

Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?

Oct 20
Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?

The Play On Sarepta Therapeutics

Sep 26

Sarepta Therapeutics Muscles Up In DMD Race

Sep 19
User avatar

ELEVIDYS Launch And Calculated Expansions Set To Skyrocket Revenue Growth

Broad approval of ELEVIDYS for Duchenne muscular dystrophy signifies potential revenue growth due to strong early launch performance.

Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity

Jul 24

Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%

Jul 05
Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%

Revenue & Expenses Breakdown

How Sarepta Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:SRPT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 252,414-2725270
30 Jun 252,482-585640
31 Mar 252,233-2485640
31 Dec 241,9022355580
30 Sep 241,6401225260
30 Jun 241,505475180
31 Mar 241,403174980
31 Dec 231,243-5364820
30 Sep 231,105-6914710
30 Jun 231,003-9084550
31 Mar 23976-1,1154900
31 Dec 22933-7034510
30 Sep 22876-7164090
30 Jun 22835-5073650
31 Mar 22766-3572830
31 Dec 21702-4192830
30 Sep 21646-4862910
30 Jun 21600-6343050
31 Mar 21573-7043060
31 Dec 20540-5543180
30 Sep 20495-6013130
30 Jun 20450-5303130
31 Mar 20407-6563070
31 Dec 19381-7152850
30 Sep 19365-6202680
30 Jun 19345-5702450
31 Mar 19323-4032270
31 Dec 18301-3622080
30 Sep 18274-2451780
30 Jun 18241-2161530
31 Mar 18203-1701330
31 Dec 17155-51123166
30 Sep 17103-1151050
30 Jun 1757-124990
31 Mar 1722-123870
31 Dec 165-267810
30 Sep 161-243850
30 Jun 161-239780
31 Mar 161-218730
31 Dec 151-220660
30 Sep 150-200550
30 Jun 151-177530
31 Mar 154-169520

Quality Earnings: SRPT is currently unprofitable.

Growing Profit Margin: SRPT is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: SRPT is unprofitable, but has reduced losses over the past 5 years at a rate of 27.2% per year.

Accelerating Growth: Unable to compare SRPT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SRPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (55.7%).

Return on Equity

High ROE: SRPT has a negative Return on Equity (-20.57%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/04 05:18
End of Day Share Price 2026/02/04 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sarepta Therapeutics, Inc. is covered by 54 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Huidong WangBarclays
Yun ZhongBerenberg